TABLE 4.

Therapeutic effect of LPC in combination with colistin, tigecycline, or imipenem in murine peritoneal sepsis model with A. baumannii Ab186

Treatmenta	n	Log10 CFU/g (mean ± SEM)		% sterile blood cultures	Mouse survival (%)b
		Spleen	Lungs
CTL	13	9.79 ± 0.06	9.63 ± 0.13	0	0*
LPC	15	7.73 ± 0.49	7.45 ± 0.48	46.67c	46.67c**
CST	15	5.48 ± 0.09c	6.45 ± 0.84c	53.33c	53.33c**
LPC+CST	15	3.71 ± 1.09c,d	3.90 ± 1.12c,d	66.67c	66.67c**
TGC	15	9.60 ± 0.07	9.59 ± 0.13	0d	0d**
LPC+TGC	15	6.81 ± 0.98c,e	6.47 ± 1.06c,e	33.33c,e	33.33c,e**
IMP	15	9.33 ± 0.10c	9.60 ± 0.06d	0d	0d*
LPC+IMP	15	6.61 ± 0.65c,d	7.36 ± 0.75c,e	33.33c,e	33.33c,e*

^aCTL, control (no treatment); LPC, lysophosphatidylcholine; CST, colistin; TGC, tigecycline; IMP, imipenem.

^b*, mouse mortality was recorded over 24 h; **, mouse mortality was recorded over 72 h.

^cP < 0.05 compared to the controls.

^dP < 0.05 compared to the LPC group.

^eP < 0.05 compared to the TGC or IMP group.